Importance of presumed germline pathogenic variants and genetic support after tumor-only sequencing

被引：0
|
作者：
Kawamura, Miyuki [1 ]
Matsumoto, Koji [1 ]
Morita, Mitsunori [1 ]
Sakai, Hideki [1 ]
Onoe, Takuma [1 ]
Urakawa, Yusaku [2 ,3 ]
Sugawara, Hiromi [4 ]
Ueno, Sayaka [5 ]
Sudo, Tamotsu [5 ,6 ]
机构：
[1] HCC, Dept Med Oncol, Osaka, Japan
[2] Okayama Univ, Dept Clin Gen Dent & Pharm Sci, Okayama, Japan
[3] Kobe City Med Ctr, Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan
[4] HCC, Dept Clin Genet, Osaka, Japan
[5] HCC, Dept Translat Res, Osaka, Japan
[6] HCC, Dept Clin Ctr Canc Genom & Clin Res, Osaka, Japan
来源：
CANCER SCIENCE | 2022年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J7-2-6
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Optimization of Population Frequency Cutoffs for Filtering Common Germline Polymorphisms from Tumor-Only Next-Generation Sequencing Data
    McNulty, Samantha N.
    Parikh, Bijal A.
    Duncavage, Eric J.
    Heusel, Jonathan W.
    Pfeifer, John D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (05): : 903 - 912
  • [42] Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups
    Asmann, Yan W.
    Parikh, Kaushal
    Bergsagel, P. Leif
    Dong, Haidong
    Adjei, Alex A.
    Borad, Mitesh J.
    Mansfield, Aaron S.
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [43] Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing
    Yamamoto, Yoshihiro
    Kanai, Masashi
    Kou, Tadayuki
    Sugiyama, Aiko
    Nakamura, Eijiro
    Miyake, Hidehiko
    Yamada, Takahiro
    Nishigaki, Masakazu
    Kondo, Tomohiro
    Murakami, Hiromi
    Torishima, Masako
    Matsumoto, Shigemi
    Kosugi, Shinji
    Muto, Manabu
    JOURNAL OF HUMAN GENETICS, 2020, 65 (02) : 125 - 132
  • [44] Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing
    Yoshihiro Yamamoto
    Masashi Kanai
    Tadayuki Kou
    Aiko Sugiyama
    Eijiro Nakamura
    Hidehiko Miyake
    Takahiro Yamada
    Masakazu Nishigaki
    Tomohiro Kondo
    Hiromi Murakami
    Masako Torishima
    Shigemi Matsumoto
    Shinji Kosugi
    Manabu Muto
    Journal of Human Genetics, 2020, 65 : 125 - 132
  • [45] Limited Independent Follow-Up with GermlineTesting of Variants Detected inBRCA1andBRCA2by Tumor-Only Sequencing
    Nowlen, Carol J.
    Daniels, Molly
    Uzunparmak, Burak
    Dumbrava, Ecaterina E. Ileana
    Yuan, Ying
    Patel, Keyur P.
    Rayes, Nadine
    Harkenrider, Jacqueline
    Wathoo, Chetna
    Veazie, Jennifer
    Luna, Krystle A.
    Wang, Wanlin
    Horombe, Chacha
    Javle, Milind
    Ahnert, Jordi Rodon
    Yap, Timothy A.
    Arun, Banu
    Lu, Karen H.
    Meric-Bernstam, Funda
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2024, 7 (01) : 7 - 17
  • [46] Germline BAP1 mutations misreported as somatic based on tumor-only testing
    Abdel-Rahman, Mohamed H.
    Rai, Karan
    Pilarski, Robert
    Davidorf, Frederick H.
    Cebulla, Colleen M.
    FAMILIAL CANCER, 2016, 15 (02) : 327 - 330
  • [47] Identification of Germline Variants in Tumor Genomic Sequencing Analysis
    Montgomery, Nathan D.
    Selitsky, Sara R.
    Patel, Nirali M.
    Hayes, D. Neil
    Parker, Joel S.
    Weck, Karen E.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (01): : 123 - 125
  • [48] Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data
    Oh, Sehyun
    Geistlinger, Ludwig
    Ramos, Marcel
    Morgan, Martin
    Waldron, Levi
    Riester, Markus
    JCO CLINICAL CANCER INFORMATICS, 2020, 4 : 321 - 335
  • [49] Prevalence of pathogenic germline variants in the circulating tumor DNA testing
    Yamamoto, Yoshihiro
    Fukuyama, Keita
    Kanai, Masashi
    Kondo, Tomohiro
    Yoshioka, Masahiro
    Kou, Tadayuki
    Quy, Pham Nguyen
    Kimura-Tsuchiya, Reiko
    Yamada, Takahiro
    Matsumoto, Shigemi
    Kosugi, Shinji
    Muto, Manabu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (10) : 1554 - 1561
  • [50] Prevalence of pathogenic germline variants in the circulating tumor DNA testing
    Yoshihiro Yamamoto
    Keita Fukuyama
    Masashi Kanai
    Tomohiro Kondo
    Masahiro Yoshioka
    Tadayuki Kou
    Pham Nguyen Quy
    Reiko Kimura-Tsuchiya
    Takahiro Yamada
    Shigemi Matsumoto
    Shinji Kosugi
    Manabu Muto
    International Journal of Clinical Oncology, 2022, 27 : 1554 - 1561
12345